TD Cowen Initiates Coverage On Kalaris Therapeutics with Buy Rating

Benzinga Newsdesk www.benzinga.com Neutral 71.7%

Neg 0% Neu 71.7% Pos 0%

TD Cowen analyst Tara Bancroft initiates coverage on Kalaris Therapeutics (NASDAQ:KLRS) with a Buy rating.

Comments

No comments yet. Be the first!